Stratasys (SSYS) is slated to release second-quarter 2024 results on Aug. 29.The Zacks Consensus Estimate for Stratasys’ second-quarter revenues is pegged at $148.08 million, indicating a year-over-year decrease of 7.31%. The consensus mark for the bottom line is pegged at a loss of 4 cents per share. SSYS posted non-GAAP earnings of 4 cents per share in the year-ago quarter.Its earnings beat the Zacks Consensus Estimate twice in the trailing four quarters, matched once and missed once, the average surprise ...

Core Viewpoint - The collaboration between CollPlant Biotechnologies and Stratasys aims to develop 3D printed breast implants that can regenerate natural breast tissue and degrade over time, addressing a $3 billion market opportunity in the breast implant sector [1][2][3]. Company Overview - CollPlant is focused on regenerative and aesthetic medicine, utilizing its proprietary rhCollagen technology for tissue regeneration and organ manufacturing [8]. - Stratasys is a leader in polymer 3D printing solutions, providing innovative technologies across various industries, including healthcare [6][8]. Market Opportunity - The global breast implant market is estimated at $3 billion, with breast reconstruction and augmentation being among the most common plastic surgery procedures worldwide [3]. - CollPlant's implants are designed to provide a revolutionary alternative to traditional silicone implants, which carry risks of complications [2][3]. Technological Development - The pre-clinical study will test the implants' ability to promote natural tissue growth and biodegradation, marking a significant advancement in regenerative medicine [1][2]. - Stratasys has adapted its Origin printer to produce the 200cc regenerative implants, with initial study results expected in the first half of 2025 [3][4]. Safety and Efficacy - Previous pre-clinical studies indicated positive outcomes, including well-developed connective tissue and initial biodegradation of the implants, confirming their safety profile [4].

Stratasys (SSYS) announced the launch of the latest innovation in dental 3D printing technology, DentaJet XL. This latest 3D printer aims to reduce costs and improve dental lab productivity with its Super High-Speed mode, large print tray, minimal post-processing workflow and larger resin cartridges.  The new printer is designed to work with minimal human intervention. It could reduce labor costs up to 90% with its advanced software prep, unattended printed and curing and print management features. The prin ...

Stratasys (SSYS) and Ricoh USA, Inc. have announced the commencement of a clinical study to evaluate the efficacy of 3D printed anatomical models in preoperative planning and tumor excision. This innovative approach aims to challenge the current standard of care, which relies solely on CT or MRI imaging.The study, which enrolled its first patient recently, will compare surgical outcomes between two groups, one using 3D printed models alongside traditional imaging for planning and another using imaging alone ...

Stratasys and Ricoh co-sponsor clinical study comparing the efficacy of 3D printed models to traditional CT or MRI scanning for bone tumor excision planningEXTON, Pa. and EDEN PRAIRIE, Minn. and REHOVOT, Israel, June 26, 2024 /PRNewswire/ -- Ricoh USA, Inc. and Stratasys Ltd. (NASDAQ: SSYS) today announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology. The study will assess the efficacy of patient-specific 3D pri ...

Stratasys (SSYS) has announced a strategic partnership with AM Craft to expand the demand for flight-certified 3D printed parts in the aviation industry. This collaboration involves a definitive commercial agreement and a strategic investment by Stratasys in AM Craft.The appeal of additive manufacturing as a supply chain solution is particularly strong due to the long sustainment life of aircraft and the challenges associated with forecasting and stocking replacement parts.Through this partnership, Stratasy ...

Stratasys (SSYS) has introduced its latest innovation, the J5 Digital Anatomy 3D printer, which is designed to meet the rising need for affordable and high-fidelity anatomical models. This advanced printer aims to help hospitals, medical device manufacturers and research institutions improve patient outcomes, streamline their operations and accelerate the time-to-market for new products.Key benefits of the J5 Digital Anatomy printer include enhanced surgical planning through the production of life-like and ...

Stratasys (SSYS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual in ...

Core Viewpoint - Stratasys is experiencing ongoing losses and declining revenue primarily due to a challenging macroeconomic environment, rather than company-specific issues. The stock has seen a decline of over 30% year-to-date, and while the company is managing to reduce cash burn and maintain a healthy balance sheet, the outlook remains cautious [1][2][9]. Market Conditions - The additive manufacturing sector, including Stratasys, is facing a constrained customer capital expenditure environment, leading to delays in purchases and longer sales cycles. This trend is expected to persist throughout 2024 [1][4]. - Stratasys believes it is gaining market share despite flat revenue outside of divestitures, with a modest improvement in sales cycles reported in Q1 [1][4]. Business Updates - Stratasys has launched new products aimed at mass production, including the F3300, which offers double the throughput of standard FDM systems and targets high-end markets. Initial orders have exceeded expectations, with significant revenue anticipated in the second half of the year [4]. - The company has also introduced the H350 version 1.5 and new materials for FDM, expanding applications in industries such as aerospace and medical [4]. Financial Analysis - In Q1, Stratasys generated $144 million in revenue, a decline of 3.5% year-over-year, with product revenue down approximately 2%. System revenue fell roughly 19% year-over-year, while consumables revenue increased by about 10% [5]. - The company expects revenue in 2024 to be between $630 million and $645 million, representing approximately 1.6% growth at the midpoint, although skepticism exists regarding achieving this target due to ongoing macroeconomic challenges [5][9]. Profitability and Cash Flow - Stratasys' gross profit margins have remained stable, supported by strong consumables revenue. Operating expenses increased by roughly 7% year-over-year, impacting profitability, but the company generated $7 million in cash from operations and was free cash flow positive in Q1 [7][9]. - The company maintains around $160 million in cash and cash equivalents, providing flexibility amid ongoing challenges [9]. Acquisition Offer - An acquisition offer from Nano Dimension remains on the table, providing a potential safety net for Stratasys if business struggles continue. The offer represents a significant premium compared to the current share price [10].

Core Insights - Stratasys (SSYS) is enhancing its additive manufacturing capabilities through regular updates, indicating strong long-term prospects for the company [1][2] - The company has established a new Fused Deposition Modeling (FDM) standard with the release of the F3300, achieving up to 2X throughput compared to standard FDM [1] - Stratasys has launched new products and software aimed at improving efficiency and expanding material options in additive manufacturing [4][5] Financial Projections - For 2024, management projects revenues between $630 million and $645 million, with non-GAAP earnings per share expected to be in the range of 12-19 cents [3] - The Zacks Consensus Estimate for Stratasys' 2024 revenues is $634.66 million, reflecting a year-over-year growth of 1.13% [3] - The consensus estimate for 2024 earnings is 15 cents per share, indicating a year-over-year growth of 36.36% [3] Product Innovations - The introduction of SAF HighDef Printing capabilities and the H350 V1.5 printer aims to enhance precision and detail in additive manufacturing, particularly for aerospace, automotive, and healthcare sectors [4] - The Direct-to-Garment solution for the J850 TechStyle printer allows full-color multi-material 3D printing directly on garments, promoting customization and sustainability [4] - The validation of Somos NeXt resin for NEO stereolithography printers expands material options for automotive and consumer products [2] Market Position and Competition - Stratasys holds a 7% market share in the additive manufacturing sector, significantly lower than competitors like Seiko Epson (33%), Konica Minolta (19%), and Hewlett Packard Enterprise (5%) [6] - The company has faced a 32.3% decline in share price year-to-date, contrasting with the 19.3% growth of the Zacks Computer and Technology sector, attributed to intense competition [5] Customer Engagement - Stratasys has established an Industrial Customer Advisory Board to gather feedback and insights from customers, aimed at fostering innovation in the additive manufacturing sector [6]